Register Login

Krystal Biotech (KRYS)

(99% Positive) Krystal Biotech (KRYS) Announces Enrollment Update for sheet Due to Patient Enrollment Issues, Regulatory Process

Full text
Register to leave comments
  • News bot Jan. 30, 2026, 8:15 a.m.

    📋 Krystal Biotech (KRYS) - Clinical Trial Update

    Filing Date: 2026-01-12

    Accepted: 2026-01-12 07:50:51

    Event Type: Clinical Trial Update

    Event Details:

    Krystal Biotech (KRYS) Announces Clinical Trial Update Krystal Biotech (KRYS) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: sheet, year
    • Diseases/Conditions: rare disease, San Francisco tomorrow
    • Collaboration: J.P. Morgan Healthcare Conference Preliminary
      • targeting larger indications such as KB408 for alpha-1 antitrypsin deficiency and KB707 for non-small cell lung cancer.To achieve the Company’s broader ambitions in rare disease, the Company’s corporate objectives for 2026

    🔬 Clinical Development Pipeline (Krystal Biotech):

    Product Type Development Stage Therapeutic Area Source
    KB801 BIOLOGICAL Phase PHASE1 Neurotrophic Keratitis ClinicalTrials.gov
    KB803 BIOLOGICAL Phase PHASE3 Dystrophic Epidermolysis Bullosa ClinicalTrials.gov
    KB707 BIOLOGICAL Phase PHASE1 Lung Cancer, Non-small Cell ClinicalTrials.gov
    Docetaxel DRUG Phase PHASE1 Lung Cancer, Non-small Cell ClinicalTrials.gov
    Chemotherapy DRUG Phase PHASE1 Lung Cancer, Non-small Cell ClinicalTrials.gov
    Pembrolizumab (KEYTRUDA®) DRUG Phase PHASE1 Lung Cancer, Non-small Cell ClinicalTrials.gov
    KB105 BIOLOGICAL Phase PHASE1 TGM-1 Related Autosomal Recessive Congenital Ichthyosis ClinicalTrials.gov
    KB407 (Nebulization) BIOLOGICAL Phase PHASE1 Cystic Fibrosis ClinicalTrials.gov
    Placebo OTHER Phase PHASE2 Autosomal Recessive Ichthyosis ClinicalTrials.gov
    Topical Beremagene Geperpavec BIOLOGICAL Phase PHASE3 Dystrophic Epidermolysis Bullosa ClinicalTrials.gov
    Placebo gel BIOLOGICAL Phase PHASE1 Dystrophic Epidermolysis Bullosa ClinicalTrials.gov
    Open Label Topical Beremagene Geperpavec (B-VEC) BIOLOGICAL Phase PHASE3 Dystrophic Epidermolysis Bullosa ClinicalTrials.gov
    KB301 BIOLOGICAL Phase PHASE1 Skin Roughness ClinicalTrials.gov
    KEYTRUDA ®( Pembrolizumab) DRUG Phase PHASE1 Cancer ClinicalTrials.gov
    Opdualag DRUG Phase PHASE1 Cancer ClinicalTrials.gov
    0.9% Normal Saline (NS) DRUG Phase PHASE1 Wrinkles in Decolletage ClinicalTrials.gov
    KB304 BIOLOGICAL Phase PHASE1 Wrinkles in Decolletage ClinicalTrials.gov
    KB408 (Nebulization) DRUG Phase PHASE1 Alpha 1-Antitrypsin Deficiency ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Krystal Biotech
    • Ticker Symbol: KRYS

Search

News categories